Helminthiasis
2
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
3100%
+ 1 programs with unclassified modality
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Human BioSciencesWV - Martinsburg
1 programCombined water, sanitation, and hygieneN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Allergy TherapeuticsAlbendazole
GSKAlbendazole
Human BioSciencesCombined water, sanitation, and hygiene
Clinical Trials (3)
Total enrollment: 359,561 patients across 3 trials
Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH)
Start: Oct 2017Est. completion: Jul 2024357,716 patients
Phase 3Completed
Bioequivalence Study of Albendazole 400 mg Tablets in Chinese Population
Start: Apr 2012Est. completion: Jun 201256 patients
Phase 1Completed
Spillover Effects of Water, Sanitation, and Hygiene Interventions on Child Health
Start: Jan 2015Est. completion: May 20161,789 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs, potential near-term approvals
Small Molecule is the dominant modality (100% of programs)
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.